Skip to main content

Table 7 Disease-free survival of AML patients in relation to gene polymorphism of CYP2B6 and CYP3A4

From: Impact of Cytochromes P450 3A4 and 2B6 gene polymorphisms on predisposition and prognosis of acute myeloid leukemia: an Egyptian case-control study

  n 9 months Cumulative Survival (%) Median Survival time (95%CI) (months) p value
Whole group 30 46.6 9.0 (5.8-12.2)  
CYP2B6
 Wild 12 63.5 *  
 Mutant 18 38.5 8.0 (6.0-10.0) 0.352
CYP3A4
 Wild 20 50.7 * 0.195
 Mutant 10 36.0 7.0 (4.3-9.7)  
Single vs. Combined
 Single Mutation 12 46.9 * 0.265
 Combined Mutations 8 31.3 7.0 (4.7-9.3)  
  1. *No median survival time because more than half of the patients were alive free of disease